This oped was originally published on Foresight Global Health on 3rd June 2021. Innovations in diabetes treatment and management have made enormous contributions to global health over the past 100 years, but there are still obstacles that must be overcome to slow the growth of the disease and reduce its impact. Exactly a century ago,...
Read moreWHA 74 – Constituency Statement on agenda items 13.4 Global strategy and plan of action on public health, innovation and intellectual property (Document A74/9), and 13.6 Substandard and falsified medical products (Document A74/9) IFPMA and GSCF, supported by ICBA welcome the WHA resolution on “Strengthening Local Production of Medicines and Other Health Technologies to Improve...
Read moreWHA 74 – Constituency Statement on agenda item 17 WHO’s work in health emergencies and strengthening preparedness for health emergencies and agenda item 18 mental health preparedness for and response to the COVID-19 pandemic IFPMA and GSCF, supported by ICBA, welcome the opportunity to make this constituency statement in relation to agenda item 17 on...
Read moreThis statement is delivered by IAPO on behalf of IAS, IDF, IEA, IHF, IFPMA, WFPHA, ISN, and WONCA. We welcome and endorse the decision made by the 148th Session of the Executive Board in January 2021 to recommend that the 74th World Health Assembly consider and adopt the WHO Flagship Global Patient Safety Action Plan...
Read moreThe 74th World Health Assembly, taking place in extraordinary circumstances, represents a critical milestone in analyzing the world’s response to the COVID-19 pandemic. Member States will engage in conversations on improving current systems for pandemic surveillance and response, against the backdrop of having multiple effective, safe and quality COVID-19 vaccines available. Since the last World...
Read more21 May 2021 – Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. Despite a massive effort to scale up and produce billions of vaccine doses, COVID-19 vaccines currently are not equally reaching all priority populations worldwide. The innovative vaccine manufacturers and biotech companies...
Read moreThis blog was originally published on Media Planet Clinical Trials Campaign on 20 May 2021. “The biopharmaceutical industry and regulatory authorities have been working to ensure clinical trials have been progressing in all diseases throughout the global pandemic. When the COVID-19 pandemic began, most of our focus went to ‘how can my family and I...
Read moreInnovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines.
Read moreOn 14 May 2020, we released our first Regulatory Guiding Principles in the unprecedented and unknown context of the COVID-19 pandemic. One year on and we are still facing the impact of this public health emergency, yet we have seen many advancements and successes.
Read moreGeneva, 7 May 2021 – The R&D-based biopharmaceutical industry is fully committed to enhancing public health through responsible sharing of clinical trial data in a manner that ensures safeguarding the privacy of patients, clinical investigators and trial participants; respecting the integrity of national regulatory systems; and maintaining incentives for investment in biomedical research. We recognize...
Read moreThe decision of the US administration to support a patent waiver for COVID-19 vaccines is disappointing. We are fully aligned with the goal to ensure COVID-19 vaccines are quickly and equitably shared around the world.
Read more